Abstract
The potential of human glucagon-like peptide-1 (hGLP-1) as a therapeutic agent is limited by its high aggregation propensity. We show that hGLP-1 forms amyloid-like structures that are preceded by cytotoxic aggregates, suggesting that aggregation of biopharmaceuticals could present a cytotoxic risk to patients besides the reported increased risk in immunogenicity.
Keywords: hGLP-1, protein aggregation, biopharmaceuticals, diabetes, amyloid fibrils, Alzheimer's disease
Protein & Peptide Letters
Title: Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1)
Volume: 16 Issue: 12
Author(s): S. Poon, N. R. Birkett, S. B. Fowler, B. F. Luisi, C. M. Dobson and J. Zurdo
Affiliation:
Keywords: hGLP-1, protein aggregation, biopharmaceuticals, diabetes, amyloid fibrils, Alzheimer's disease
Abstract: The potential of human glucagon-like peptide-1 (hGLP-1) as a therapeutic agent is limited by its high aggregation propensity. We show that hGLP-1 forms amyloid-like structures that are preceded by cytotoxic aggregates, suggesting that aggregation of biopharmaceuticals could present a cytotoxic risk to patients besides the reported increased risk in immunogenicity.
Export Options
About this article
Cite this article as:
Poon S., Birkett R. N., Fowler B. S., Luisi F. B., Dobson M. C. and Zurdo J., Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1), Protein & Peptide Letters 2009; 16 (12) . https://dx.doi.org/10.2174/092986609789839232
DOI https://dx.doi.org/10.2174/092986609789839232 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interaction of Endocannabinoid Receptors with Biological Membranes
Current Medicinal Chemistry Adipose Tissue Derived Stem Cells for Regeneration and Differentiation into Insulin-Producing Cells
Current Stem Cell Research & Therapy Processing of Amyloid Precursor Protein and Amyloid Peptide Neurotoxicity
Current Alzheimer Research Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System
Current Pharmaceutical Design The Role of JNK Signalling in Responses to Oxidative DNA Damage
Current Drug Targets Carbon Nanotubes in the Diagnosis and Treatment of Malignant Melanoma
Anti-Cancer Agents in Medicinal Chemistry Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Intrahypothalamic Administration of Modafinil Increases Expression of MAP-Kinase in Hypothalamus and Pons in Rats
CNS & Neurological Disorders - Drug Targets Synthetic Methods of Quinoline Derivatives as Potent Anticancer Agents
Mini-Reviews in Medicinal Chemistry Interventional Radiology in Paediatrics
Current Pediatric Reviews Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Current Molecular Medicine Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism β-Galactosylated Alkyl-oligoamine Derivatives of Polyethylenimine Enhanced pDNA Delivery into Hepatic Cells with Reduced Toxicity
Current Nanoscience Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Anti-Cancer Agents in Medicinal Chemistry Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets A Novel Monoclonal Antibody Against the C-terminus of β-Tubulin Recognizes Endocytic Organelles in Trypanosoma cruzi
Protein & Peptide Letters HDACs and HDAC Inhibitors in Urothelial Carcinoma – Perspectives for an Antineoplastic Treatment
Current Medicinal Chemistry